NYSE: LH · Diagnostics & Research

Labcorp Holdings (LH) fair value and price range

As of 16 Nov 2026, Faircurve's model values Labcorp Holdings (LH) at $465.68 a share. The stock last closed at $372.46, which puts the model's fair value 25.0% above the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.

Revalued . Price is the close of 16 Nov 2026. Labcorp Holdings Inc.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$465.68midpoint of 2,000 simulations
Last close$372.46NYSE: LH
Gap to fair value+25.0%fair value against price
Model verdictLow evidence gradeevidence grade: Low

This week, in three parts

What happenedThe run of 16 Nov 2026 moved the fair value from $435.58 to $465.68 (+6.9%).

What the model makes of itThe price of $372.46 is 25.0% below it. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.

What's nextNext report on 16 Feb 2027. Options prices imply a move of about 7% either way over the next month. On the model's Scorecard Leaders list since 9 Nov 2026 (a strategy with a proving record). The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give LH?

The calibrated range for LH over 63 trading days is $342.78 to $406.40. It sits around the last close, and its width comes from the volatility that LH's own options imply (25% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $366.38 to $573.93. In 79% of the simulations the fair value came out above the price the model ran on.

$267.73$783.49
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $465.68. Dashed line: the last close, $372.46.

Faircurve Insights · 16 Nov 2026

Labcorp Holdings, Inc. offers vital diagnostic laboratory services. They enable medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators and patients to make well-informed and confident choices.

Faircurve's model put the fair value of Labcorp Holdings at $465.68 a share on 16 Nov 2026. The previous run, on 7 Nov 2026, gave $435.58, so the fair value moved +6.9%. The calibrated range over 63 trading days runs from $342.78 to $406.40. It is built around the price using the volatility implied by the stock's own options, calibrated weekly against realised prices. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence as low, on input completeness, comparable-company agreement and range width. It does not say whether the fair value is right.

On quality, the model gives Labcorp Holdings an overall score of 58 out of 100 against comparable companies. Capital discipline is strongest at 80, with net buybacks at 2.2% of market value against a peer median of 1.2%. Earnings quality scores 77, with FCF to net income at 1.28x against a peer median of 1.07x. The balance sheet is weakest at 31, with net debt to EBITDA at 3.02x against a peer median of 2.58x. The comparable companies are Illumina, Quest Diagnostics, Mettler-Toledo, IQVIA, Waters, Agilent, Medpace and Revvity.

Written from the figures on this page for the 16 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does LH report earnings, and how has the stock reacted?

Labcorp Holdings's next earnings report is scheduled for 16 Feb 2027. Companies can move their dates.

Options prices on 16 Nov 2026 imply a move of about 5.9% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. LH's 30 day implied volatility works out to about 7.3% over one month.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across LH's last 8 reports, ignoring direction, was 5.4%.

0%5%10%15%no quote5.0%29 Apr '256.4%5.8%24 Jul '255.8%10.0%28 Oct '255.2%1.4%17 Feb '266.2%0.5%30 Apr '267.4%0.7%30 Jul '266.8%9.2%27 Oct '2614.0%11.2%28 Oct '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in LH

0%5%10%15%28 Oct '26 report27 Oct '26 report30 Jul '26 report30 Apr '26 report17 Feb '26 report7% at 16 Nov '2617 Nov '2516 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 7% on 17 Nov 2025, reached 11% on 23 Apr 2026 and reads 7% on 16 Nov 2026. The marks are report dates.

How does LH score on business quality?

Labcorp Holdings's overall quality score is 58 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.468.7%ROIC8.9%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).771.28xFCF / net income1.07x
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.607.2%Revenue growth, trailing11.8%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.802.2%Net buybacks / market value1.2%
Balance sheetNet debt to EBITDA and interest coverage.313.02xNet debt / EBITDA2.58x
StabilityDownside volatility of the EBITDA margin over the last five years.593.0 ptsEBITDA margin downside volatility, 5y6.4 pts

How does LH compare with similar companies?

The companies in diagnostics & research closest to Labcorp Holdings in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
ILMN Illumina, Inc.$198.00$172.96-12.6%Fairly valued
DGX Quest Diagnostics Incorporated$262.21$314.32+19.9%Undervalued
MTD Mettler-Toledo International Inc.$1,727.26$1,679.36-2.8%Fairly valued
IQV IQVIA Holdings Inc.$264.73$335.69+26.8%Undervalued
WAT Waters Corporation$453.42$337.75-25.5%Overvalued
A Agilent Technologies, Inc.$172.92$176.09+1.8%Fairly valued
MEDP Medpace Holdings, Inc.$648.20$717.73+10.7%Fairly valued
RVTY Revvity, Inc.$148.85$185.05+24.3%Undervalued

What the comparable companies' multiples alone would give for LH, the peer-implied price, is $1,275.85 a share on this run. The fair value weighs that against the company's own multiple.

All diagnostics & research stocks ranked by gap to fair value

Labcorp Holdings at a glance

Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices.

Market value
$30.1B
Sector
Healthcare
Industry
Diagnostics & Research
Revenue expected, next twelve months
$15.5B
Consensus revenue growth, next fiscal year
+6.3%
Analysts with estimates
10
Beta to the US market
0.31
First valued by Faircurve
1 May 2026

How the fair value is worked out: the model prices Labcorp Holdings on the value of the whole business, debt included, against the revenue analysts expect next year (forward EV/Sales), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for LH was $435.58. As of 16 Nov 2026 it is $465.68, a change of +6.9%. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Labcorp Holdings's valuation

Is Labcorp Holdings stock undervalued or overvalued?

Faircurve's model puts LH's fair value at $465.68 a share against a last close of $372.46, as of 16 Nov 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.

What is LH's fair value?

$465.68 a share as of 16 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $366.38 to $573.93.

What price range does the model give LH?

$342.78 to $406.40 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does Labcorp Holdings report earnings next?

The next report is scheduled for 16 Feb 2027. Companies can move their dates.

How much has LH moved on past earnings reports?

Across its last 8 reports the median two session move was 5.4%, ignoring direction. The largest was +11.2% around the report of 28 Oct 2026.

How confident is the model in this valuation?

The model's evidence grade for LH is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on LH

The model has an idea open on LH under Scorecard Leaders since 9 Nov 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on LH with their outcomes. A free account is enough.

Keep reading